Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Biocardia Inc

Healthcare US BCDA

1.0USD
0.03(3.43%)

Last update at 2026-06-23T20:00:00Z

Day Range

0.931.02
LowHigh

52 Week Range

1.003.20
LowHigh

Fundamentals

  • Previous Close 0.97
  • Market Cap13.68M
  • Volume475614
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-8.25400M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM -4.96200M
  • Diluted EPS TTM-1.23

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -8.22800M -7.94600M -11.57100M -11.90700M -12.62300M
Minority interest - - - - -
Net income -8.22800M -7.94600M -11.57100M -11.91300M -12.62100M
Selling general administrative 3.32M 3.67M 4.39M 4.42M 5.09M
Selling and marketing expenses - - - - -
Gross profit -0.50500M -4.32900M -7.24900M -10.54900M 1.01M
Reconciled depreciation 0.02M 0.07M 0.08M 0.08M 0.06M
Ebit -8.27800M -8.00100M -11.64400M -11.98300M -12.63000M
Ebitda -7.77300M -7.93400M -11.56000M -11.90100M -12.56300M
Depreciation and amortization 0.51M 0.07M 0.08M 0.08M 0.07M
Non operating income net other - - - - -
Operating income -8.27800M -8.00100M -11.64400M -11.90100M -12.63000M
Other operating expenses 8.28M 8.06M 12.12M 13.25M 13.64M
Interest expense - - - 0.00600M 0.00900M
Tax provision - - - - -
Interest income - - - - 0.00900M
Net interest income - - - - 0.00900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -7.94600M 0.24M 0.00600M -0.00200M
Total revenue 0.00000M 0.06M 0.48M 1.35M 1.01M
Total operating expenses 7.77M 3.67M 4.39M 13.25M 13.64M
Cost of revenue 0.51M 4.39M 7.73M 11.90M 0.00000M
Total other income expense net 0.05M 0.05M 0.07M -0.00600M 0.00700M
Discontinued operations - - - - -
Net income from continuing ops -8.22800M -7.94600M -11.57100M -11.90700M -12.62300M
Net income applicable to common shares - - - -11.90700M -12.62300M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 3.41M 3.72M 2.99M 9.79M 15.72M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.22M 0.25M 0.29M 0.50M 0.46M
Total liab 2.52M 2.89M 4.59M 4.90M 5.34M
Total stockholder equity 0.90M 0.84M -1.60300M 4.89M 10.38M
Deferred long term liab - - - - -
Other current liab 1.35M 1.02M 1.82M 1.62M 1.44M
Common stock 0.01M 0.00500M 0.02M 0.02M 0.02M
Capital stock 0.01M 0.00500M 0.02M 0.02M 0.02M
Retained earnings -168.34900M -160.12100M -152.17500M -140.60400M -128.69700M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.17M 0.17M
Cash 2.50M 2.37M 1.10M 7.36M 12.87M
Cash and equivalents - - - - -
Total current liabilities 2.43M 2.32M 3.61M 3.58M 3.71M
Current deferred revenue - 0.53M 0.56M 0.96M 1.53M
Net debt -1.96800M -1.42000M 0.21M -5.73200M -11.00400M
Short term debt 0.44M 0.39M 0.33M 0.32M 0.24M
Short long term debt - - - - -
Short long term debt total 0.53M 0.95M 1.31M 1.63M 1.87M
Other stockholder equity 169.23M 160.95M 150.55M 145.48M 139.06M
Property plant equipment - - - 1.76M 2.06M
Total current assets 2.73M 2.62M 1.46M 7.86M 13.48M
Long term investments - - - - -
Net tangible assets - - - 4.89M 10.38M
Short term investments - - - - -
Net receivables 0.02M 0.00000M 0.06M 0.20M 0.15M
Long term debt - - - - -
Inventory - - - -0.20100M -
Accounts payable 0.64M 0.39M 0.89M 0.68M 0.51M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.17M 0.17M 0.17M 0.17M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 0.68M 1.10M 1.53M 1.93M 2.24M
Capital lease obligations 0.53M 0.95M 1.31M 1.63M 1.87M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.00600M -0.01200M -0.07000M -0.11600M
Change to liabilities - - - -0.50200M -0.07500M
Total cashflows from investing activities -0.00700M -0.00600M -0.01200M -0.07000M -0.11600M
Net borrowings - - - - -
Total cash from financing activities 7.57M 9.30M 3.73M 5.12M 1.95M
Change to operating activities - - - 0.34M -0.07300M
Net income -8.22800M -7.94600M -11.57100M -11.90700M -12.62300M
Change in cash 0.12M 1.27M -6.26000M -5.50900M -8.53500M
Begin period cash flow 2.37M 1.10M 7.36M 12.87M 21.41M
End period cash flow 2.50M 2.37M 1.10M 7.36M 12.87M
Total cash from operating activities -7.43600M -8.02600M -9.97400M -10.56100M -10.36600M
Issuance of capital stock 8.69M 10.55M 4.39M 5.54M 2.00M
Depreciation 0.02M 0.07M 0.08M 0.08M 0.06M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - 0.51M
Change to account receivables -0.02000M 0.10M 0.12M -0.05400M 0.09M
Sale purchase of stock - - - - -
Other cashflows from financing activities -0.19700M -1.25200M -0.66200M -0.41800M -0.05400M
Change to netincome - - - - 1.68M
Capital expenditures 0.00700M 0.00600M 0.01M 0.07M 0.12M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.14300M -1.21700M 0.13M -0.21400M 0.52M
Stock based compensation 0.43M 0.74M 1.03M 1.18M 1.66M
Other non cash items 0.48M 0.33M 0.35M 0.29M 0.02M
Free cash flow -7.44300M -8.03200M -9.98600M -10.63100M -10.48200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BCDA
Biocardia Inc		 0.03 3.43% 1.00 - - 11.35 15.28 23.81 -3.1591
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Biocardia Inc

320 Soquel Way, Sunnyvale, CA, United States, 94085

Key Executives

Name Title Year Born
Dr. Peter A. Altman Ph.D. CEO, Pres & Director 1967
Mr. David McClung Chief Financial Officer 1963
Mr. Edward M. Gillis Sr. VP of Devices 1962
Dr. Ian McNiece Ph.D. Chief Scientific Officer 1954
Dr. Sujith Shetty Chief Medical Officer and VP of Clinical & Regulatory NA
Dr. Peter A. Altman Ph.D. CEO, President & Director 1967
Mr. Edward M. Gillis Senior Vice President of Devices 1962
Dr. Sujith Shetty MBBS Chief Medical Officer and VP of Clinical & Regulatory NA
Ms. Miranda Peto Benvenuti Investor Relations Executive NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.